…
GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -46.69M | -63.43M | -51.03M | -57.89M | -48.27M |
| Net income | -93.33M | -63.14M | -50.27M | -54.12M | -48.27M |
| Selling general administrative | 19.09M | 17.11M | 16.74M | 14.36M | 11.41M |
| Gross profit | 0.07M | 1.16M | 10.16M | - | 0.00M |
| Reconciled depreciation | 0.21M | 0.26M | 0.27M | 0.28M | 0.28M |
| Ebit | -47.61M | -63.71M | -51.78M | -61.67M | -51.78M |
| Ebitda | -47.40M | -63.45M | -51.51M | -61.39M | -51.51M |
| Depreciation and amortization | 0.21M | 0.26M | 0.27M | 0.28M | 0.28M |
| Operating income | -47.40M | -63.45M | -51.51M | -61.39M | -51.51M |
| Other operating expenses | 47.48M | 64.61M | 61.67M | 61.39M | 51.51M |
| Interest expense | 46.64M | 0.02M | 0.00M | 0.00M | 0.00M |
| Interest income | 0.71M | 0.02M | 0.48M | 3.50M | 3.23M |
| Net interest income | 0.71M | 0.02M | 0.48M | 3.50M | 3.23M |
| Income tax expense | 46.64M | -0.28M | -0.75M | -3.78M | 3.23M |
| Total revenue | 0.07M | 1.16M | 10.16M | 0.00M | 0.00M |
| Total operating expenses | 47.48M | 64.61M | 61.67M | 61.39M | 51.51M |
| Cost of revenue | - | - | - | - | 0.00M |
| Total other income expense net | 0.71M | 0.02M | 0.48M | 3.50M | 3.23M |
| Net income from continuing ops | -46.69M | -63.43M | -51.03M | -57.89M | -48.27M |
| Net income applicable to common shares | -46.69M | -63.43M | -51.03M | -57.89M | -48.27M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 45.32M | 51.81M | 94.35M | 142.83M | 167.97M |
| Other current assets | 1.82M | 2.84M | 533.80M | 1238.33M | 4326.32M |
| Total liab | 6.90M | 8.88M | 12.74M | 14.61M | 13.77M |
| Total stockholder equity | 38.41M | 42.93M | 81.60M | 128.22M | 154.20M |
| Other current liab | 5.23M | 6.99M | 8.72M | 9.44M | 8.71M |
| Common stock | 0.06M | 0.05M | 0.05M | 0.05M | 0.04M |
| Capital stock | 0.06M | 0.05M | 0.05M | 0.05M | 0.04M |
| Retained earnings | -456.49M | -419.59M | -372.90M | -309.47M | -258.44M |
| Other liab | - | - | - | 0.26M | - |
| Other assets | 0.00M | 0.00M | 1.61M | -0.00M | 0.00M |
| Cash | 41.79M | 47.87M | 90.25M | 137.03M | 158.20M |
| Total current liabilities | 6.84M | 8.88M | 11.82M | 12.43M | 10.95M |
| Net debt | -40.98M | -46.95M | -88.33M | -134.22M | -154.58M |
| Short term debt | 0.74M | 0.92M | 1.00M | 0.90M | 0.80M |
| Short long term debt total | 0.81M | 0.92M | 1.92M | 2.82M | 3.62M |
| Other stockholder equity | 494.84M | 462.46M | 454.45M | 437.64M | 412.60M |
| Property plant equipment | - | 0.99M | 1.95M | 0.62M | 0.82M |
| Total current assets | 43.79M | 50.71M | 90.25M | 138.27M | 162.53M |
| Net tangible assets | - | 42.93M | 81.60M | 128.22M | 154.20M |
| Net receivables | 0.18M | 0.14M | 0.00M | 0.00M | 0.19M |
| Inventory | - | -0.14M | -533.81M | -1237.09M | -4322.18M |
| Accounts payable | 0.87M | 0.97M | 2.11M | 2.09M | 1.44M |
| Accumulated other comprehensive income | - | - | - | - | -1.86M |
| Common stock total equity | - | - | - | 0.05M | 0.04M |
| Retained earnings total equity | - | - | - | -309.47M | -258.44M |
| Non currrent assets other | 0.76M | 0.10M | 2.15M | 1.61M | 1.61M |
| Non current assets total | 1.53M | 1.10M | 4.09M | 4.56M | 5.44M |
| Capital lease obligations | 0.81M | 0.92M | 1.92M | 2.82M | 3.62M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -0.08M | -0.01M | -0.07M | -0.14M | -0.13M |
| Change to liabilities | -1.14M | 0.02M | 1.38M | 1.48M | 0.57M |
| Total cashflows from investing activities | -0.08M | -0.01M | -0.07M | -0.14M | -0.13M |
| Total cash from financing activities | 4.16M | 10.72M | 18.14M | 0.41M | 129.45M |
| Change to operating activities | -3.52M | -1.18M | 3.28M | 0.02M | 0.06M |
| Net income | -46.69M | -63.43M | -51.03M | -57.89M | -48.27M |
| Change in cash | -42.38M | -46.78M | -21.17M | -51.72M | 85.99M |
| Begin period cash flow | 90.25M | 137.04M | 158.20M | 209.92M | 123.92M |
| End period cash flow | 47.87M | 90.25M | 137.04M | 158.20M | 209.92M |
| Total cash from operating activities | -46.46M | -57.49M | -39.24M | -51.98M | -43.33M |
| Issuance of capital stock | 4.16M | 10.70M | 17.82M | 0.00M | 128.43M |
| Depreciation | 0.21M | 0.26M | 0.27M | 0.28M | 0.28M |
| Sale purchase of stock | - | - | 18.14M | 0.41M | 129.45M |
| Other cashflows from financing activities | -0.08M | 0.03M | 0.32M | 0.41M | 1.02M |
| Change to netincome | 4.69M | 6.84M | 6.90M | 6.22M | 4.59M |
| Capital expenditures | 0.08M | 0.01M | 0.07M | 0.14M | 0.13M |
| Cash flows other operating | - | - | 3.23M | -2.07M | -0.49M |
| Cash and cash equivalents changes | - | - | -21.17M | -51.72M | 85.99M |
| Change in working capital | -4.66M | -1.17M | 3.93M | -1.21M | 0.08M |
| Stock based compensation | 3.86M | 6.09M | 6.90M | 6.22M | 4.59M |
| Other non cash items | 0.83M | 0.75M | 0.68M | 0.62M | 0.00M |
| Free cash flow | -46.54M | -57.50M | -39.31M | -52.13M | -43.46M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
-1.25 3.07% |
39.45 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
- -% |
536.45 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-9.75 1.02% |
948.01 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
9708 Medical Center Drive, Rockville, MD, United States, 20850
240 243 1201
35
| Name | Title | Year Born |
|---|---|---|
| Mr. Harout Semerjian | CEO, Pres & Director | 1970 |
| Mr. Brian M. Hahn | Sr. VP & CFO | 1974 |
| Dr. John L. Magnani Ph.D. | Sr. VP of Research & Chief Scientific Officer | 1953 |
| Ms. Stephanie R. Irish CPA | VP of Accounting | 1971 |
| Mr. Christian Dinneen-Long | VP, Corp. Counsel & Corp. Sec. | NA |
| Mr. Armand Girard | Chief Bus. Officer and Sr. VP of Strategy & Corp. Devel. | 1969 |
| Mr. Bruce Johnson | Sr. VP & Chief Commercial Officer | NA |
| Dr. Edwin Rock M.D., Ph.D. | Chief Medical Officer | NA |
| Mr. Harout Semerjian | CEO, President & Director | 1970 |
| Ms. Rachel K. King | Co-Founder & Director | 1959 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.